Sopartec
VC Fund
Bel, Belgium
Sopartec is a VC fund in Bel focused on Biotechnology and Farming. Sopartec is the technology transfer and investment company owned by the Université catholique de Louvain.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Sopartec invests in
Stages Sopartec invests in
Countries Sopartec invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $1.4M–$1.6M
Investment Focus
Industry
- Biotechnology 3 (75%)
- Farming 1 (25%)
- Medical 1 (25%)
- Hardware 1 (25%)
- Agriculture 1 (25%)
Stage
- Series B 2 (50%)
- Seed 1 (25%)
- Series D 1 (25%)
Country
- Belgium 3 (75%)
- France 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Philippe Durieux
Chief Executive Officer
|
Chief Executive Officer | Total investments: 3 | Find email | |
|
Vivian Capart
Financial and administrative
|
Financial and administrative | Total investments: 0 | Find email | |
François Blondel
Director
|
Director | Total investments: 3 | Find email | |
Xavier Bastin
CEO
|
CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BiocSol
|
BiocSol focus on sustainable microbial-based crop protection. | $5.5M / Seed / Nov 20, 2024 | |
| CISSOID is a Fabless Semiconductor company, leader in High Temperature Electronics. They develop and sell Integrated Circuits (IC) designed for the highest reliability in the widest range of temperatures. Their products will operate at least from -55°C to +225°C. They have been tested from -200°C to +300°C. The reliability of CISSOID productsis based on long years of experience in silicon technologies, design for reliability, assembly techniques and test.CISSOID products are commonly used under extreme conditions and harsh environments, for example in demanding Oil&Gas, Aerospace and Automotive applications. They enable exploitation of deep oil resources, energy savings in aircrafts and automobiles, optimal exploitation of geothermal resources, etc.CISSOID proposes a portfolio of High Temperature standard products, such as Voltage Regulators, Voltage References, Clock Generators & Timers, Analog-to-Digital Converters, Amplifiers, High-Voltage MOSFET's and Drivers. Custom solutions can also be developed as an Application Specific Monolithic IC (ASIC) or as a Hybrid multichip assembly solution.Most of CISSOID’s products are built on Silicon-on-Insulator (SOI), a fabrication process that offers tremendous advantages for High Temperature operation and high levels of radiation (Rad-Hard products). Cissoid’s products inherit over 20 years of R&D activities in the field of SOI and was the very first company to exploit this technology.CISSOID produces: DC-DC converters (High Temperature) Linear Voltage Regulators (High Temperature) MOSFET and Switches (High Temperature) Oscillators and Timers (High Temperature) Motor Drivers ((High Temperature) Logic Gates (High Temperature) Operational Amplifiers (High Temperature) Analog-to-DIgital Converters (High Temperature) | $1.6M / Series B / Apr 02, 2008 | ||
| VIRIDAXIS, a spin‑off of Louvain Catholic University, uses an innovative technology to mass-produce parasitoids. These are then supplied to Belgian and multinational companies operating in this sector. Expansion of its R&D activity now enables the company to develop new products and increase its production capacity. | $1.4M / Series B / Oct 22, 2007 | ||
| Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improvedbiodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP). | $12.8M / Series D / Jul 03, 2007 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sopartec invest in?
Sopartec invests primarily in Biotechnology, Farming and Medical startups, most often at Series B and Seed stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sopartec invest in?
Sopartec typically joins rounds of $1.4M–$1.6M at Series B. These are whole funding-round sizes, not Sopartec's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sopartec took part in.
How do I contact Sopartec?
Public channels for Sopartec include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sopartec?
The team at Sopartec includes Philippe Durieux (Chief Executive Officer), Vivian Capart (Financial and administrative) and François Blondel (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
